Loading...
NPI 1730186354 · Las Vegas, NV · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Dhan Kaushal is a hematology & oncology physician provider located in Las Vegas, Nevada. This profile covers 65 Medicare and 8 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Dhan Kaushal |
| Address | 3730 S Eastern Ave |
| City | Las Vegas |
| State | NV |
| ZIP | 89169 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | June 29, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.4M |
| Medicaid | $82K |
Taxonomy and service mix are consistent with an oncology-focused practice: the top Medicare revenue drivers include high-cost oncology drugs and advanced diagnostic imaging such as J9271 (pembrolizumab, $395.6K, 30.6% of Medicare revenue), A9595 (piflufolastat f-18, $266.5K, 20.6%), and 78815 (PET/CT, $203.5K, 15.7%). The presence of chemotherapy infusion codes (96413), supportive agents (J0881, J0897), and frequent lab panels (85025, 80053, 82728) further indicate a practice that delivers systemic cancer therapy alongside imaging-guided diagnostic management.
Revenue concentration on Medicare is high: the top 3 Medicare codes by revenue account for 66.9% of this provider's total Medicare revenue, driven particularly by J9271, A9595, and 78815. This concentration implies the provider’s Medicare income is heavily dependent on a small set of costly oncology drugs and PET-based imaging services rather than broad primary-care E/M revenue.
On the Medicaid side the revenue mix is markedly different and heavily E/M–weighted: the top 3 Medicaid codes by revenue account for 89.7% of this provider's total Medicaid revenue, with 99214 alone representing $54.5K (66.6% of Medicaid revenue). Medicaid activity is concentrated in office evaluation and management and infusion/support services (J1756 and 96365), suggesting Medicaid patients are managed primarily through clinic visits and iron/infusion therapies rather than high-cost radiopharmaceuticals.
Payer mix is Medicare-dominant in scale: the provider reported Total Medicare revenue of $1.4M compared with Total Medicaid revenue of $82K, indicating Medicare is the primary revenue source. This imbalance suggests the provider’s business and cash flow are driven largely by Medicare oncology episodes and drug reimbursements rather than the Medicaid caseload.
Competitive standing is mixed across codes: the provider is a notably high-volume reporter for J0881 (ranks #54 of 1114 providers nationally; 95th percentile; notably above typical national volume) and for Medicare 99214 (ranks #24631 of 479517 providers nationally; 95th percentile; notably above typical national volume), signaling above-typical activity for these supportive and E/M services. By contrast, J9271 (ranks #1274 of 1841; 31th percentile; typical, unremarkable volume) is a more modest national participant and A9595 (ranks #90 of 528; 83th percentile; typical, unremarkable volume) and 78815 (ranks #1280 of 6566; 80th percentile; typical, unremarkable volume) show typical but not dominant positioning for high-cost imaging and radiopharmaceuticals.
In-state (Medicaid) competitive posture appears modest: Medicaid 99214 ranks #859 of 2254 providers in-state (62th percentile; typical, unremarkable volume), while J1756 (iron sucrose) ranks #49 of 55 providers in-state (11th percentile; typical, unremarkable volume) and 96365 ranks #49 of 59 (17th percentile; typical, unremarkable volume). These ranks indicate reasonable clinic visit volume locally but limited standing among in-state peers for infusion product codes.
Operational footprint includes integrated imaging and laboratory diagnostics: frequent use of PET radiotracers (A9595, A9552), PET/CT procedures (78815, 78816), and routine labs (85025, 80053, 82728, 82306) indicates the provider either refers heavily to or coordinates closely with imaging and lab services as part of oncology workups. This pattern supports a care model combining systemic therapy with imaging-driven diagnostics and serial lab monitoring common in hematology/oncology practice.
Long tenure suggests an established practice presence: the NPI was enumerated on 2005-06-29 (~21 years ago), which is consistent with a stable, long-running provider likely to have established referral relationships and repeat oncology patient panels. That longevity, combined with the concentrated Medicare drug and imaging revenue streams, points to an experienced oncology clinician whose practice economics are anchored in Medicare-funded cancer therapies and diagnostics.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
65 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 9,200 | $40 | $395.6K |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | 550 | $480 | $266.5K |
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 160 | $1,260 | $203.5K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 53,600 | $1 | $107.2K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 720 | $90 | $63.4K |
| J0897 | Injection, denosumab, 1 mg | 2,820 | $20 | $50.8K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 100 | $290 | $29.7K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | 180 | $130 | $24.1K |
| 78816 | The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The… | 20 | $1,280 | $20.5K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 200 | $100 | $20.4K |
Showing 1–10 of 65
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 65 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
65 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 29 | 40 | 13,000 | $40 | $625.8K |
| A9595 | 1 | 10 | 150 | $490 | $109.6K |
| J0897 | 41 | 70 | 3,630 | $20 | $94.6K |
| 78815 | 9 | 60 | 60 | $930 | $80.4K |
| J0881 | 2 | 30 | 17,400 | $1 | $49.5K |
| 82306 | 8 | 30 | 80 | $30 | $41.9K |
| J1439 | 8 | 10 | 24,000 | $1 | $27.7K |
| J9217 | 13 | 40 | 120 | $130 | $23.9K |
| 96413 | 38 | 70 | 210 | $100 | $23.7K |
| 99232 | 1,111 | 1,340 | 140 | $60 | $23.7K |
Showing 1–10 of 65
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
8 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 560 | $100 | $54.5K |
| J1756 | Injection, iron sucrose, 1 mg | 80 | $140 | $11K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 130 | $60 | $8K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 40 | $150 | $6.2K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 140 | $10 | $990 |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 20 | $40 | $620 |
| 82728 | The lab analyst measures the level of ferritin, an important protein composed of about 20 percent iron. Ferritin also acts as an iron reserve in the body, and is present in serum in only minute… | 30 | $10 | $360 |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 20 | $10 | $190 |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
8 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 859 | 2,250 | 290 | $60 | $138K |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 69 | 70 | 2,110 | $10 | $114.5K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 49 | 60 | 2,150 | $20 | $93.7K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 117 | 130 | 1,600 | $1 | $74.9K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 526 | 780 | 90 | $100 | $46.6K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 110 | 160 | 1,190 | $1 | $39.8K |
| 82728 | The lab analyst measures the level of ferritin, an important protein composed of about 20 percent iron. Ferritin also acts as an iron reserve in the body, and is present in serum in only minute… | 87 | 90 | 720 | $1 | $7K |
| J1756 | Injection, iron sucrose, 1 mg | 49 | 60 | 6,940 | $1 | $5K |
Other providers in the same ZIP code as Dhan Kaushal, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.